Effect of cell determinant (CD)34+ cell dose on the cost and consequences of peripheral blood stem cell transplantation for non-Hodgkin's lymphoma patients in front-line therapy

European Journal of Cancer

Volumn 36, Issue 18, 2000, Pages 2360-2367

  Limat, S ^a   Woronoff Lemsi, M C ^a   Milpied, N ^b   Chartrin, I ^c   Ifrah, N ^d   Deconinck, E ^a   Gressin, R ^e   Colombat, P ^c   Cahn, J Y ^a   Arveux, P ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE TOURS   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

^e GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Autologous stem cell transplantation; CD34; Cost; Granulocyte macrophage colony stimulating factor (GM CSF); Lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; MELPHALAN; PREDNISONE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VINCRISTINE;

ADOLESCENT; ADULT; ANTIGEN DETECTION; ARTICLE; CLINICAL TRIAL; COMPUTER PROGRAM; COST CONTROL; ECONOMIC ASPECT; FEMALE; HEALTH CARE UTILIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD COMPONENT REMOVAL; COST-BENEFIT ANALYSIS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOXORUBICIN; FEMALE; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDNISONE; VINCRISTINE;

EID: 0033710103     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00327-0     Document Type: Article

References (31)

1. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: Hematologic recovery and costs. A randomized, controlled trial
2. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy
3. Factors that influence collection and engraftment of autologous peripheral blood stem cells
4. Autologous transplantation of blood stem cells mobilized with filgrastim alone in 93 patients with malignancies: The number of CD34+ cells reinfused is the only factor predicting both granulocyte and platelet recovery
5. Pediatric experience with autologous peripheral blood progenitor cell transplantation influence of CD34+ cell dose in engraftment kinetics
6. Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation
7. Economic rationale for infusing optimal numbers of CD34+ cells in peripheral blood progenitor cell transplants
8. Effect of cell dose on resource utilization in patients undergoing transplant with peripheral blood progenitor cells
9. Effect of CD34+ cell dose on resource utilization in patients after high-dose chemotherapy with peripheral blood stem cell support
10. A predictive model for aggressive non Hodgkin's lymphomas
11. Cost comparative study of autologous peripheral blood progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin's lymphoma patients
12. A guide to the economic analysis of clinical practices
13. Economic analyses of bone marrow and blood stem cell transplantation for leukemia and lymphoma: What do we know?
14. Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ cell content
15. Back-up bone marrow is frequently inefficient in patients with poor peripheral blood stem cell mobilization
16. High CD34+ cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation
17. Granulocyte-macrophage colony-stimulating factors accelerate hematopoietic recovery after autologous bone marrow or peripheral blood progenitor cell transplantation and high-dose chemotherapy for lymphoma
18. Report of an international workshop to standardize response criteria for Non-Hodgkin's lymphomas
19. CD34+CD33-cells influence days to engraftment and transfusion requirements in autologous blood stem-cell recipients
20. 6/kg CD34+ cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantation
21. Cost-effectiveness of CD34+ dose in peripheral blood progenitor cell transplantation for non-Hodgkin's lymphoma patients. A single center study
22. Management strategies for the hard-to-mobilize patient
23. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells
24. The absolute number of circulating CD34+ cells predicts the number of hematopoietic stem cells that can be collected by apheresis
25. When to harvest peripheral blood stem cells after mobilization therapy: Prediction of CD34-positive cell yield by preceding day CD34-positive concentration in peripheral blood
26. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma
27. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies
28. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients. Results of a phase I/II trial
29. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy
30. Abrogation of post-myeloablative chemotherapy neutropenia by ex-vivo expanded CD34+ cells